Omeros Corporation (OMER) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Omeros Corporation  (NASDAQ: OMER)


Omeros's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Omeros's ROI in the second quarter of 2026?
Omeros Corporation achieved a return on average invested assets (ROI) of 227.29 % in its second quarter of 2026, this is above OMER's average return on investment of -198.22%.
Omeros Corporation invested over the 12 months ending in its second quarter of 2026 $55 million

Despite the deterioration in its net income, company has improved ROI compared to the first quarter of 2026.

Within the Healthcare sector 3 other companies had a higher return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. .

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM - - - - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 192 74 87 -133 -134
Return On Investment (TTM) 227.29 % -325.36 % 4.4 % - -
OMER's Overall Ranking # # # # # 4595
Seq. Investment Change TTM - - - - -
Seq. Net Income Change TTM 44.86 % - - - -
Net Income (TTM) in Millions 125 86 -3 -121 -122

OMER Company Profile >> Back to OMER Roi Comparisons >> See Annual OMER Return On Investment



Return On Investment OMER's Ranking
Within: No.
Industry # 2
Sector # 4
Overall #

Return On Investment Statistics
High Average Low
198.34 %
-198.22 %
-1159.69 %
(Jun 30 2026)   (Sep 30 2012)



  News about Omeros Corporation Return on Investment ROI

SEATTLE, WA In a significant development for both the field of hematology and the biopharmaceutical indu...

November 21, 2024

Innovative Biologics Achieve Milestones: Omeros Corporation Nears Resubmission of BLA for Pioneering Antibody Treatment in TA-TMA SEATTLE, WA In a significant development for both the field of hematology and the biopharmaceutical industry, Omeros Corporation (Nasdaq: OMER) has provided an encouraging update on their continuing efforts to resubmit the biologics license application (BLA) for narsoplimab. Narsoplimab, Omeros promising first-in-class antibody, targets the MASP-2 enzyme, a crucial component of the lectin pathway, which plays a pivotal role in complement-mediated diseases. The focus of its application lies within the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a severe and potentially life-threatening disorder.Following the company’s recent quarterly earnings release and a detailed call with analysts and stakeholders, Omeros has disclosed its current standing and strategic progress toward the BLA resubmission. The company confirmed it was waiting for pivotal feedback from regulatory authorities, which is anticipated to guide the final adjustments required prior to resubmission.





Financial Statements
Omeros's II. Quarter Investments $ 192 Millions OMER's Balance sheet
Omeros's II. Quarter Income $ 13 Millions Quarterly OMER's Income Statement
OMER's Income by Division See OMER's Income by Division


OMER Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 87 -113 18 307 367
Y / Y Investment Growth - - -94.04 % -16.57 % 68.73 %
Net Income in Millions -3 -157 -118 47 194
Y / Y Net Income Growth - - - -75.59 % -
Annual Return On Investment -3.84 % - -644.67 % 15.47 % 52.86 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
OMER's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for OMER's Competitors
Subscribers only: Roi for Omeros's Suppliers
Subscribers only: Return On Investment for OMER's Customers

Other Ratios
OMER's Roa OMER's Inventory Turnover Ratio OMER's Growth Rates OMER's Dividend Statistics
OMER's Profitability Ratios OMER's Asset Turnover Ratio OMER's Dividend Growth
OMER's Roe OMER's Valuation Ratios OMER's Financial Strength Ratios OMER's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Stablecoin Development Corporation  618.18 %
Omeros Corporation  198.34 %
Elutia Inc   191.75 %
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %

Date modified: 2026-09-26T07:07:31+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.